Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,842
  • Shares Outstanding, K 6,990
  • Annual Sales, $ 0 K
  • Annual Income, $ 1,440 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow 17.90
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +80.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +18.15%
on 12/03/25
4.60 -16.52%
on 11/17/25
+0.02 (+0.52%)
since 11/05/25
3-Month
1.93 +98.96%
on 09/18/25
12.46 -69.18%
on 10/21/25
+1.49 (+63.40%)
since 09/05/25
52-Week
1.15 +233.91%
on 04/09/25
12.46 -69.18%
on 10/21/25
+1.72 (+81.13%)
since 12/05/24

Most Recent Stories

More News
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

NERV : 3.84 (+2.67%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 3.84 (+2.67%)
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

NERV : 3.84 (+2.67%)
Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences: Q2 Earnings Snapshot

NERV : 3.84 (+2.67%)
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025...

NERV : 3.84 (+2.67%)
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

NERV : 3.84 (+2.67%)
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 3.84 (+2.67%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 3.84 (+2.67%)
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

NERV : 3.84 (+2.67%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 3.84 (+2.67%)

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

3rd Resistance Point 4.26
2nd Resistance Point 4.05
1st Resistance Point 3.95
Last Price 3.84
1st Support Level 3.64
2nd Support Level 3.43
3rd Support Level 3.33

See More

52-Week High 12.46
Fibonacci 61.8% 8.14
Fibonacci 50% 6.80
Fibonacci 38.2% 5.47
Last Price 3.84
52-Week Low 1.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar